Harman-d3

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]W E Müller, et al. On the neuropharmacology of Harmane and other beta-carbolines. Pharmacol Biochem Behav. 1981 May;14 (5) :693-9.|[3]Musgrave IF, et, al. Harmane produces hypotension following microinjection into the RVLM: possible role of I (1) -imidazoline receptors. Br J Pharmacol. 2000 Mar;129 (6) :1057-9.|[4]Glover V, et, al. β-Carbolines as selective monoamine oxidase inhibitors:In vivo implications|[5]Umezawa K, et, al. Comutagenic effect of norharman and harman with 2-acetylaminofluorene derivatives. Proc Natl Acad Sci U S A. 1978 Feb;75 (2) :928-30.|[6]E D Louis, et al. Harmane induces anxiolysis and antidepressant-like effects in rats. Ann N Y Acad Sci. 2005 Aug 9;65 (3) :391-6.|[7]Yoo Jung Yang, et al. Effects of harman and norharman on dopamine biosynthesis and L-DOPA-induced cytotoxicity in PC12 cells. Eur J Pharmacol. 2008 Jun 10;587 (1-3) :57-64.